The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody
Abstract
Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II trial with the natural killer (NK)-cell–activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fcγ-receptor III (CD16 antigen) and the Hodgkin's-associated CD30 antigen, respectively. Median counts of NK cells and of all lymphocyte subsets were considerably decreased in the patients before therapy. HRS-3/A9 was administered 4 times every 3 to 4 days, starting with 1 mg/m2. The treatment was well tolerated, and the maximum tolerated dose was not reached at 64 mg/m2, the highest dose administered because of the limited amounts of HRS-3/A9 available. Side effects were rare and consisted of fever, pain in involved lymph nodes, and a maculopapulous rash. A total of 9 patients developed human antimouse Ig antibodies, and 4 patients developed an allergic reaction after attempted retreatment. A total of 1 complete and 1 partial remission (lasting 16 and 3 months, respectively), 3 minor responses (1 to 11+ months), and 1 mixed response were achieved. There was no clear-cut dose-side effect or dose-response correlation. Our results encourage further clinical trials with this novel immunotherapeutic approach and emphasize the necessity to reduce the immunogenicity of the murine bispecific antibodies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two Phase 1 clinical studies performed with this molecule led to one complete remission (CR) and one partial remission (PR) in a group of 15 treated patients; 14 this was followed by one CR and three PR in a second clinical trial. 15”
From Bispecific antibodies for cancer therapy: The light at the end of the tunnel? (2009) · cites this paper as [14]
Citations
Cites
Stein, H., Mason, D., Gerdes, J., O'Connor, N., Wainscoat, J. S., Pallesen, G., Gatter, K. C., Falini, B., Delsol, G., Lemke, H., et al. (1985) · Blood · doi:10.1182/blood.v66.4.848.848 · Cited by 1,849
"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T. D., & Winter, G. P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 882
Stein, H., Mason, D., Gerdes, J., et al. (1985) · Blood · doi:10.1182/blood.v66.4.848.bloodjournal664848 · Cited by 717
Hybrid hybridomas and their use in immunohistochemistry
Milstein, C., & Cuello, A. C. (1983) · Nature · doi:10.1038/305537a0 · Cited by 525
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351
Caligiuri, M. A., Murray, C., Robertson, M. J., Wang, E. S., Cochran, K., Cameron, C. A., Schow, P. W., Ross, M. E., Klumpp, T. R., & Soiffer, R. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116161 · Cited by 267
Preliminary trial of specific targeting therapy against malignant glioma
Nitta, T., Yagita∥, H., Okumura, K., Sato, K., & Ishii, S. (1990) · The Lancet · doi:10.1016/0140-6736(90)90205-j · Cited by 235
Canevari, S., Stoter, G., Arienti, F., Bolis, G., Colnaghi, M. I., Re, E. D., Eggermont, A. M. M., Goey, S. H., Gratama, J. W., Lamers, C. H. J., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1463 · Cited by 187
Valone, F. H., Kaufman, P. A., Guyre, P. M., Lewis, L. D., Memoli, V. A., Deo, Y. M., Graziano, R. F., Fisher, J. L., Meyer, L. A., & Mrozek-Orlowski, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2281 · Cited by 180
Cure of Xenografted Human Tumors by Bispecific Monoclonal Antibodies and Human T Cells
Renner, C., Jung, W. E., Şahin, U., Denfeld, R. W., Pohl, C., Trümper, L. H. P., Hartmann, F., Diehl, V., van Lier, R. A. W., & Pfreundschuh, M. G. (1994) · Science · doi:10.1126/science.8171337 · Cited by 156
Self-citation
Research works printed but not linked: 1
- Weiner, 1995, Phase I Trial of 2B1, a bispecific monoclonal antibody targeting c-erB-2 and FcγRIII., Cancer Res, 55, 4586
Cited by
Sorted by citations
Items 101–149 of 149
Monoclonal Antibodies in Cancer Treatment
Alpaugh, K. R., & von Mehren, M. (1999) · BioDrugs · doi:10.2165/00063030-199912030-00004 · Cited by 10
Poynton, C. H. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/0-306-48388-2_14 · Cited by 10
Müller, D., & Kontermann, R. E. (2007) · Wiley eBooks · doi:10.1002/9783527619740.ch15 · Cited by 10
Dillman, R. O. (2009) · Springer eBooks · doi:10.1007/978-90-481-2289-9_10 · Cited by 9
Specific Targeting Immunotherapy of Cancer with Bispecific Antibodies.
Kudo, T., Suzuki, M., Katayose, Y., Shinoda, M., Sakurai, N., Kodama, H., Ichiyama, M., Takemura, S., Yoshida, H., Saeki, H., et al. (1999) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.188.275 · Cited by 9
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions
Zhang, H., Yan, Y., Yi, S., & Sun, Q. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2492936 · Cited by 8
Müller, D., & Kontermann, R. E. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch11 · Cited by 9
Dillman, R. O. (2003) · Springer eBooks · doi:10.1007/978-94-017-2757-0_10 · Cited by 7
Bispecific Antibodies: Developments and Current Perspectives
Kontermann, R. E. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_1 · Cited by 7
New concepts for relapsed Hodgkin's disease
Josting, A., Raemaekers, J. M. M., Diehl, V., & Engert, A. (2002) · Annals of Oncology · doi:10.1093/annonc/13.s1.117 · Cited by 7
Relapsed and Refractory Hodgkin Lymphoma
Josting, A., & Biermann, P. J. (2010) · Springer eBooks · doi:10.1007/978-3-642-12780-9_13 · Cited by 6
Emerging drugs for Hodgkin's lymphoma
Böll, B., Borchmann, P., & Diehl, V. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2010.505602 · Cited by 6
Walz, A., Andratschke, M., Wollenberg, B., Lindhofer, H., & Zeidler, R. (2005) · PubMed · Cited by 6
Kua, L. H., Ng, C. H., Tan, J. W., Tan, H. C., Seh, C. C., Wong, F. H., Ong, R., Rooney, C. M., Tan, J., Chen, Q., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.06.037 · Cited by 5
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
Reed, D. R., & Lum, L. G. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2384086 · Cited by 4
Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?
Reyes, A., Pharaon, R. R., Mohanty, A. R., & Massarelli, E. (2023) · Cancers · doi:10.3390/cancers15123162 · Cited by 4
Antikörper als spezifische Tumortherapeutika
Gramatzki, M., & Valerius, T. (1997) · Der Internist · doi:10.1007/s001080050117 · Cited by 4
Lum, L. G., & Al-Kadhimi, Z. S. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.9.1081 · Cited by 4
Bispecific Diabodies for Cancer Therapy
Arndt, M. A. E., & Krauß, J. (2003) · Humana Press eBooks · doi:10.1385/1-59259-334-8:305 · Cited by 4
Engineering antibodies for dual specificity and enhanced potency
Ko, S., & Jung, S. T. (2015) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-014-0575-6 · Cited by 4
Kumar, A., Khani, A. T., & Swaminathan, S. (2022) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2022.00024 · Cited by 3
Bispecific Antibodies and Immune Therapy Targeting
Kiprijanov, S. M. (2011) · Wiley eBooks · doi:10.1002/9783527634057.ch16 · Cited by 3
Monoklonale Antikörper: Entwicklung und klinische Perspektiven
Borchmann, P., Riethmüller, G., & Engert, A. (2001) · Der Internist · doi:10.1007/s001080170123 · Cited by 3
Les anticorps bispécifiques : une vieille histoire pleine d’avenir… avec les CAR-T !
Riffard, C., & Teillaud, J. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.02.016 · Cited by 2
Bispecific Antibodies for Arming Activated T Cells and Other Effector Cells for Tumor Therapy
Lum, L. G., & Thakur, A. B. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_14 · Cited by 2
Bispezifische Antik�rper in der H�matologie und Onkologie
Repp, R., Valerius, T., & Bargou, R. C. (2001) · Der Internist · doi:10.1007/s001080170128 · Cited by 2
Az akut mieloid leukémia kezelésének új lehetőségei: út a személyre szabott terápiás stratégiák felé
Szakács, Z., & Alizadeh, H. (2022) · Hematológia–Transzfuziológia · doi:10.1556/2068.2022.00151 · Cited by 2
Bispecific antibodies for the treatment of tumours and infectious diseases
Drakeman, D. L., Fanger, M. W., & Wallace, P. K. (1997) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.6.9.1169 · Cited by 2
Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting.
Fisher, R. I. (2001) · PubMed · Cited by 2
Trivalent and Trispecific Antibody Derivatives for Cancer Therapy
Stein, C., Schubert, I. A., & Fey, G. H. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_4 · Cited by 1
Experimentelle Therapie des Hodgkin-Lymphoms
Böll, B., Borchmann, P., & Engert, A. (2009) · Der Onkologe · doi:10.1007/s00761-009-1765-2 · Cited by 1
Biological Therapy of Non-Hodgkin's Lymphomas
Zelenetz, A. D. (2006) · Elsevier eBooks · doi:10.1016/b978-0-7216-0081-9.50019-4 · Cited by 1
Immunopathology and Immunotherapy of Hodgkin Lymphoma
Ebadi, M., Keshavarz‐Fathi, M., Zeng, Y., Gkotzamanidou, M. A., & Rezaei, N. (2020) · Springer eBooks · doi:10.1007/978-3-030-57949-4_6 · Cited by 1
Pioneering Immunotherapy Agents and Their Synergy with Radiotherapy
Zhang, S.-J., Zheng, L., Cao, L., Wang, G.-R., Xiao, Y., Wu, Q., Liu, B., & Bu, L. (2025) · Springer eBooks · doi:10.1007/978-981-96-3659-4_9 · Cited by 1
CD30: a suitable target for immunotherapy?
Borchmann, P. (2009) · Hematology Meeting Reports (formerly Haematologica Reports) · doi:10.4081/hmr.v1i8.281
Is there a role for immunotherapy in Hodgkin’s disease?
Böll, B., & Engert, A. (2009) · Hematology Meeting Reports · doi:10.4081/hmr.v2i5.757
Lejeune, M., de la Cruz‐Merino, L., & lvaro, T. (2012) · InTech eBooks · doi:10.5772/34028
Lum, L. G., & Yang, W. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.4.459
Bifunctional Antibodies: Preclinical and Clinical Applications
Shuptrine, C. W., & Weiner, L. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_10
Clinical Applications of Targeted Therapeutics
GHOSE, T. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-167-1_2
Immunopathology and Immunotherapy of Hodgkin Lymphoma
Ebadi, M., Zeng, Y., Gkotzamanidou, M. A., & Rezaei, N. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_7
Recent approaches in the treatment of Hodgkin's lymphoma.
Raida, L. (1999) · PubMed
Perhaps not everyone knows that…
(1997) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010893
Hodgkin Lymphoma in children six years Experience of Children Welfare Teaching Hospital
Mohammed, M. I., & Fadhli, A. G. S. A. (2020) · IAR Journal of Medical Sciences · doi:10.47310/iarjms.2022.v03i04.003
Antibody-Redirected T-Cell Immunotherapy for Brain Tumors
Choi, B. D. (2014) · DukeSpace (Duke University)
Gong, Y., Zhang, X., Ren, W., Peng, J., Liu, M., Jiang, L., Pei, C., Hu, X., Xu, J., Zhang, T., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114603
Humanized Mice as Models to study Human Innate Immunity and Immunotherapies
Lopez‐Lastra, S. (2017) · theses.fr (ABES) · doi:10.70675/332ff2f4z793bz4a95zbffcz4be18383be48
Metadata
- Authors
- Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., & Pfreundschuh, M.
- Affiliations
- Universitätsklinikum des Saarlandes (DE)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1997-03-15
- Volume
- 89
- Issue
- 6
- Pages
- 2042-2047
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1539079695
- Cited by
- 149
- References
- 29
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 8 · 2015: 5 · 2014: 5 · 2013: 6 · 2012: 7
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- refractory Hodgkin lymphoma, bispecific antibodies, CD16, CD30, NK cell activation, Fc gamma receptor III, immunotherapy, maximum tolerated dose, human anti-mouse antibodies, immunogenicity, allergic reactions, treatment response
- MeSH terms
- Adolescent, Adult, Antibodies, Monoclonal, Female, Hodgkin Disease, Humans, Male, Middle Aged, Remission Induction, Lymphocyte Subsets, Receptors, IgG, Ki-1 Antigen, Antibodies, Bispecific, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
